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Abstract
Background
Background: Depression is a disorder of major public health importance, in terms of its prevalence and
suffering, dysfunction, morbidity and economic burden. Depression is one of the most common
conditions for which people seek homoeopathic treatment. Objective
Objective: This study is aimed to understand
the scope of homoeopathy in depression based on the results of previous studies. Methods
Methods: A study was
done to evince the scope of homoeopathic medicines in the treatment of depression. Searches were done
in both general and specialised databases. The data were collected from peer-reviewed journals
published between January 2001 and January 2021. Efforts were made to identify published articles on
‘depression and homoeopathy, homoeopathy for depression, depressive disorder and homoeopathy,
dysthymia in homoeopathy’. Results
Results: Twenty-one relevant studies were found and included in the review.
These included systematic reviews, randomised control trials, observational studies, case series and case
reports. Even though the studies considered in the review indicate the effectiveness of Homoeopathy, it is
difficult to assess the overall effect of homoeopathy systematically, mostly because of compromised
study designs. Conclusion
Conclusion: This review has helped in synthesising the existing literature on the scope of
homoeopathy in the treatment of depression. However, in order to obtain more reliable results, betterdesigned researches, with long-term follow-ups may be planned.
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it is difficult to assess the overall effect of homoeopathy systematically, mostly because of compromised study designs. Conclusion: This
review has helped in synthesising the existing literature on the scope of homoeopathy in the treatment of depression. However, in order to
obtain more reliable results, better-designed researches, with long-term follow-ups may be planned.
Keywords: Depression, Depression rating scale, Homoeopathy, Mental Health, Narrative synthesis

Introduction
Depression (major depressive disorder [MDD] or clinical
depression) is a common, but serious mood disorder.[1] Mood
and affect in depression are unreactive to circumstance,
remaining low throughout the course of each day. In some
people, mood varies diurnally, with gradual improvement
throughout the day, only to return to a low mood on waking.[2]
Research suggests that a mixture of genetic, biological,
environmental and psychological factors play a role in
depression.[3] Depression can occur along with other serious
diseases, such as diabetes, cancer, heart disease and Parkinson’s
disease. Depression can make these conditions worse and vice
versa. Sometimes, medications taken for these diseases may
cause side effects that lead to depression symptoms.[1]
According to the International Classification of Diseases
(ICD)-10 classification of mental and behavioural disorders,
depression includes depressive episodes (F32), recurrent
depressive episodes (F33), persistent mood (affective) disorder
(F34), other mood (affective) disorder (F38) and unspecified
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mood disorder (F39).[4] The diagnostic and statistical manual
of mental disorders of the American Psychiatric Association,
currently in its fifth edition, contains disruptive mood
dysregulation disorder, MDD, persistent depressive disorder,
premenstrual dysphoric disorder, substance/medicationinduced depressive disorder, depressive disorder due to another
medical condition and other specified depressive disorder.[5]
A systematic analysis of the global burden of disease study
from 2007 to 2017 estimated that depressive disorders along
with low back pain and headache disorders are the three leading
causes of years lived with disability (YLD). Between 1990 and
2007, the number of all-age YLDs attributable to depressive
disorders increased by 33.4%.[6]
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Due to their impact and widespread prevalence, depressive
symptoms are a growing public health concern. Globally, more
than 264 million people of all ages suffer from depression.
When long-lasting and with moderate or severe intensity,
depression may become a serious disorder. It can cause the
affected person to suffer greatly and function poorly at work,
at school and in the family. At its worst, depression can lead to
suicide.[6,7] Almost 1 million lives are lost yearly due to suicide,
which amounts to 3000 suicide deaths every day.[8]
Major depressive episode (MDE) includes depressive episodes
that occur as part of a bipolar disorder, whereas MDD excludes
bipolar depression. Because the vast majority of lifetime
MDE is MDD, the difference between the two is not of great
importance. However, bipolar depression is considerably more
persistent than non-bipolar depression.[9]
A meta-analysis of prospective cohort studies indicates that
insomnia is significantly associated with an increased risk of
depression.[10] Research has also identified other risk factors for
depression like cognitions and cognitive processes; stressors;
certain sociodemographic factors, such as being female;
parental depression and certain traits, behaviour patterns and
dispositions.[11]
Effective treatments are available both when depression
occurs alone and when it co-occurs with general medical
illnesses. Barriers to diagnosing and treating depression
include stigma; patient somatisation and denial; physician
knowledge and skill deficits; limited time; lack of availability
of providers and treatments and restrictions on specialist, drug
and psychotherapeutic care.[12]
Dr Samuel Hahnemann (1796–1843), founder of Homoeopathy,
was a pioneer in the diagnosis and classification of mental
diseases. He advocated humane treatment for mental illness.
He opposed the practice of chaining mental patients and
granted respect to them which was revolutionary at its time.[13]
Homoeopathy states that the body and mind are integrated.
According to the homoeopathic concept, physical disease can
make changes in the mental/emotional state and vice versa.
It attempts to go to the core of the disease in each individual
patient. The ‘totality of symptoms’ in an individual patient
comprises all changes observable on physical as well as
mental/emotional sphere. A homoeopathic ‘similimum’ is the
medicine that matches the totality of the patient’s physical
and mental/emotional symptoms, irrespective of which came
first.[14]
Depression is one of the most common conditions for which
people seek homoeopathic treatment.[15] Various sorts of
studies have evinced the scope of homoeopathy in mental
diseases.[16-19] We found that many studies showed efficacy
in depression and the results are encouraging to collect
cumulative evidence. This study is aimed to integrate the
results of the previous studies, which have already assessed the
efficacy of homoeopathy in depression, in a systematic way.
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Methods
Study design

The study was done based on critical assessment and evaluation
of research articles, to provide an overview of the quality of
the best available evidence of homoeopathic management of
depression.

Search strategy and selection criteria

For the search and screening processes, we applied the PICO
model, which considers four facets: Population, Intervention,
Comparison and Outcomes. [20] Search was done in both
general and specialist databases such as psycINFO, Medline,
PubMed, EMBASE, Cochrane library, CINHAL, Hom-inform,
Complementary and Alternative Medicine and Wiley library.
Literature searches were carried out by one researcher from
6 January 2021 to 10 January 2021, with an updated search
from 13 January 2021 to 20 January 2021. Efforts were made
to identify published articles on ‘depression in homoeopathy,
homoeopathy for depression, MDD, MDE, depressive disorder
and homoeopathy or dysthymia in homoeopathy’. There were
1236 hits which were then subject to various filtration criteria.

Inclusion criteria

Studies reporting the homoeopathic treatment of patients
with depression or depressive disorder published in peerreviewed journals between January 2001 and January 2021
were included, because of our interest in new literature.
Adults of either sex with the primary diagnosis of depression
or depressive disorder according to standard operationalised
diagnostic criteria (Feighner criteria, research diagnostic
criteria, diagnostic and statistical manual of mental disorders
[DSM]-III, DSM-III-R, DSM-IV, DSM-5 and ICD-10) were
included in the study. It included randomized controlled trials,
cohort studies, prospective observational studies, case series,
case reports, and also conference abstracts. Only the articles
published in English were scrutinized. The studies which
compared homoeopathic intervention with allopathic medicine,
placebo or cognitive behavioural therapy were also included
in this review. Homoeopathic interventions in all forms, such
as individual and complex homoeopathic medicines, were
included.

Exclusion criteria

Studies reporting depression with substance abuse, depression
as a co-morbid disorder, and those having participants whose
primary diagnosis was not depression or depressive disorder
were excluded.

Outcome measures

Depression rating scales and standard measurements for sleep,
satisfaction or quality of life were used wherever relevant.
Beck inventory scale, Hamilton depression rating scale,
Greene climacteric scale, Montgomery and Asberg depression
rating scale, hospital anxiety and depression scale, Edinburgh
postnatal depression scale, Columbia-Suicide Severity Rating
Scale, Clinical Global Impression (CGI), Short-Form 12
(SF12), quality of life questionnaire and the Work and Social
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Disability Scale (WSDS) and the Pittsburgh Sleep Quality
Index questionnaire were used.

in detail. Finally, we excluded 129 irrelevant studies and 21
studies were included in the review.

Data management

Quality of included studies

Both independent investigators reviewed full-text versions of
the articles and articles were retained if they met the inclusion
criteria. The agreement on inclusion and exclusion assignment
was unanimous. Data collected using a tailored form was
extracted from included studies. These comprised: authors;
study design; intervention, original authors’ conclusions
about efficacy across study outcomes and adverse effects, if
reported any. All data required to answer the study questions
was available within the papers, so no contact with authors was
necessary. The authors found that there was heterogeneity in the
populations studied, the type of interventions offered, and the
outcome measures reported. It was therefore methodologically
inappropriate to combine most studies. Wherever applicable,
the results of similar studies were pooled. The results were
summarized in tables and text.

Quality assessment

Due to the heterogeneity of the type of studies, distinct assessment
tools had to be used to assess the quality of the studies. Critical
Appraisal Checklist developed by Critical Appraisal Skills
Programme for systematic review, Newcastle–Ottawa Quality
Assessment Scale for non-randomised studies, appraisal tool for
cross-sectional studies (AXIS), Institute of Health Economics
(IHE) Quality Appraisal Checklist for case series and Joanna
Briggs Institute (JBI) Critical Appraisal Checklist for Case Series
are the tools used.[21-25] After a thorough quality assessment, all
quantitative data were generated and tabulated.

Results
An adapted PRISMA flow diagram shows the process followed
to select the studies used in this report [Figure 1].[26] Nine
databases and other sources identified 1236 titles. After the
removal of duplicates, 386 titles were screened. Of these, 150
studies were deemed as potentially relevant and were reviewed

It was intended that, based on the assessment criteria
designated for each study in the respective tool, the studies
were subdivided into three categories:
1. Mild: <50% of the quality criteria met.
2. Moderate: at least 50% of the quality criteria met.
3. High: more than 70% of the quality criteria met.
A summary of the included studies is reported below, and also
in Table 1.
The systematic study on homoeopathy and depression by
Pilkington et al. in 2005 stated that the effectiveness of
homoeopathy in depression is limited due to a lack of highquality clinical trials.[27] Another systematic study by Viksveen
et al. in 2018 assessed the efficacy, effectiveness and safety of
homoeopathy in depression. Out of the 18 studies identified,
limited evidence from two placebo-controlled double-blinded
trials suggests that homoeopathic medicinal products might
be comparable to antidepressants and superior to placebo
in depression, and patients treated by homoeopaths report
improvement in depression. [28] Another semi-structured
qualitative interview study was done by Viksveen et al. in
2017, within a randomised controlled trial to learn about
depressed patients’ experiences with the treatment provided
by homoeopaths. Most of those interviewed were uncertain
about how the treatment worked but described improvements
in their mental and general state of health.[29]
In a randomised controlled clinical trial, a ‘cohort multiple
randomised controlled trial’ design was used to test the
effectiveness of adjunct treatment by homoeopaths compared
to usual care alone, over a period of 12 months in patients with
self-reported depression. The primary outcome was measured
through Patient Health Questionnaire (PHQ-9) tool and the
authors conclude by stating that an offer of treatment provided

Records identified Through Database
Searches (n=1,236)

Records excluded due to duplication
N=850

Records screened after removing
duplicates (n=386)

Reason for exclusion.
1. Depression as a secondary outcome (n =39).
Not homoeopathy (n =46)
3. Not depression (n =151)

Full text of articles assessed for eligibility
(n=150)

Studies included (n=21)

Reason for exclusion:
1. Reporting depression with substance
abuse (n =32)
2. Animal study (n =8)
3. The studies in which outcomes were not
assessed on the basis of any validated
scale (n =89)

Figure 1: Flow chart depicting the study selection
Indian Journal of Research in Homoeopathy ¦ Volume 16 ¦ Issue 4 ¦ Oct-Dec 2022

271

Moorthi, et al.: Depression: A narrative synthesis

Table 1: Summary of the included studies
S. No.

Article

Study design/sample
size/instrument used

Quality

Strength

Limitation

1

Pilkington K,
Kirkwood G, Rampes H, Fisher
P, Richardson J. Homoeopathy
for depression: A systematic
review of the research
evidence. Homoeopathy.
2005 Jul; 94 (3):153‑63. doi:
10.1016/j.homp. 2005.04.003.
PMID: 16060201
Viksveen P, Fibert P, Relton C.
Homoeopathy in the treatment
of depression: A systematic
review. European journal
of integrative medicine.
2018;22:22‑36.

CASP‑systematic
study review

High

The review addressed a clearly
focused issue. The review included
the right type of papers. The quality
of the studies was assessed properly

The results were not
combined, because of the
heterogeneity of the studies

CASP‑systematic
study review

Moderate

Quality assessments not
done. aggregated results
can be presented in
limited extent due to the
heterogeneity of studies

3

Adler UC, Paiva NM,
Cesar AT, Adler MS,
Molina A, Padula AE,
Calil HM. Homoeopathic
individualised Q‑potencies
versus fluoxetine for moderate
to severe depression:
Double‑blind, randomised
non‑inferiority trial. Evid
Based Complement Alternat
Med. 2011;2011:520182. doi:
10.1093/ecam/nep114.

CASP‑randomised
trial.
Sample size 91.
The study was
a prospective,
randomised,
double‑blind,
double‑dummy trial,
with fluoxetine as the
active control

High

4

Viksveen P, Relton C,
Nicholl J. Depressed patients
treated by homoeopaths: A
randomised controlled trial
using the ‘cohort multiple
randomised controlled trial’
(cmRCT) design. Trials.
2017;18 (1):299.

CASP‑randomised
trial.
The sample size of 485
patients.
Cohort multiple
randomised controlled
trial (cmRCT) design

Mild

The review addressed a clearly
focused issue. The right type of
papers was selected. The results of
the review are explicitly stated and it
can be applied to the local population.
The risk of bias was assessed
according to the Cochrane
Collaboration’s guidelines, focusing
on the main outcome measure for
each trial. The potential risk between
study – publication bias was also
considered.
The review used a novel approach
to the assimilation of evidence by
considering three different types
of evidence: Those assessing the
efficacy of homoeopathic medicines;
those assessing the effectiveness of
treatment by homoeopaths and those
describing the outcomes of patients
treated by homoeopaths.
It was a non‑inferiority trial.
It was double‑blinded, double‑dummy
and placebo‑controlled trial. Results
state that homoeopathy is non‑inferior
to fluoxetine. All patients underwent
the same medical and homoeopathic
assessment. Both groups
(homoeopathy n = 48, fluoxetine
n = 43) improved over time
(P < 0.001) on the Montgomery and
Åsberg Depression Rating Scale
(MADRS), with no significant
between‑group differences at 4 weeks
(95% CI‑6.95, 0.86, P=0.65) and 8
weeks (95% CI‑6.05, 0.77, P=0.97).
The pre‑fixed margin of non‑inferiority
was (Δ) 1.45, which was 1/3–1/2
of the advantage of fluoxetine over
placebo, and the minimum considered
clinical relevance. The sample
size was sufficient to establish the
non‑inferiority of homoeopathy
compared to fluoxetine.
The trial addressed a clearly
focused issue. All the patients were
randomised into groups. The use
of the cmRCT design provides the
additional benefit of testing the
acceptability of the intervention.
Questionnaires were, however,
completed by patients at home,
thereby avoiding any undue research
influence on patients

2

Only percentages (and not
numbers) were provided for
secondary outcomes. The
trial had high risk of bias
due to high attrition rates
(40% in both trial arms) and
acceptable model validity.

Less number of participants
was in the adjuvant group
than the control group.
Another limitation of this
trial was a lower 6‑month
and 12‑month questionnaire
response rate in patients who
were randomly selected to be
offered the intervention, but
who did not take up the offer.
(Contd...)
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Table 1: (Continued)
S. No.

Article

Study design/sample
size/instrument used

Quality

Strength

5.

Văcăraş V, Vithoulkas G,
Buzoianu AD, Mărginean I,
Major Z, Văcăraş V, et al.
Homoeopathic treatment
for postpartum depression:
A case report. Journal
of evidence‑based
complementary and
alternative medicine. 2017
Jul; 22 (3):381‑4.

JBI‑case report

Moderate

The dramatic improvement in the
patient’s condition with the use
of homoeopathic medication was
corroborated by all parameters
evaluated by the 3 scales routinely
used both in this department
and in this case. The patient had
improvement in functional level too

6.

Moorthi SK. Homoeopathic
treatment for Severe
Depression with Psychotic
features. International Journal
of Homoeopathic Sciences.
2020;4 (1):82‑86.

JBI‑case report

Moderate

7.

Bagherian M, Mojembari
AK, Hakami M. The effects
of homeopathic medicines
on reducing the symptoms
of anxiety and depression:
Randomized, double blind
and placebo controlled. J
Homeopath Ayurv Med
2014;3:167-1206.
Adler UC, Krüger S,
Teut M, et al. Homoeopathy
for depression: A randomised,
partially double‑blind,
placebo‑controlled,
four‑armed study
(DEP‑HOM). PLoS One.
2013;8 (9):e74537. Published
2013 Sep 23. doi: 10.1371/
journal.pone. 0074537.
Macías‑Cortés Edel
C, Llanes‑González L,
Aguilar‑Faisal L,Asbun‑Bojalil
J. Individualised
homoeopathic treatment and
fluoxetine for

CASP‑randomised
trial.
Sample size‑30.
Randomised,
double‑blind and
placebo‑controlled
trial

Mild

CASP‑randomised
trial.
Sample size‑44.
A randomised,
partially double‑blind,
placebo‑controlled,
four‑armed study

High

The history of the patient is well
depicted. The current clinical
condition of the patient on
presentation is clearly described.
The assessment methods, results and
interventions are clearly described in
tables. Improvements were measured
with scales. Patients had improved in
their functional level too
A true representative sample is used.
Non‑exposed cohorts are drawn from
different sources. Ascertainment of
exposure is from a secure record.
Demonstrated that the outcome of
interest was not present at the start of
the study. The outcome was assessed by
Hospital Anxiety and Depression Scale,
HAD. Follow‑up was long enough
The trial addresses a clearly focused
issue. Patients were properly
randomised to provide treatment. All
the patients who entered the trial were
not accounted for at its conclusion.
The results can be applied to the local
population. All clinically important
outcomes were considered

CASP‑randomised
trial.
Sample size‑133.

Mild

8.

9.

Diagnosed with major depression
according to DSM‑IV.
Moderate‑to‑severe depression was
measured according with 17‑item
HRSD. Beck Depression Inventory
and Greene Climacteric Scales were

Limitation
Another limitation was the
lack of blinding.
Potential non‑acceptance
of an offer of treatment is
a specific feature of the
cmRCT design that warrants
particular attention when
interpreting trial results.
The confidence interval
precludes any firm
conclusions from being
drawn.
The patient’s demographic
characteristics are not clearly
described. The patient’s
history is not clearly
described nor presented
as a timeline. The current
clinical condition of the
patient on presentation
is clearly described. The
assessment methods and
the results are not clearly
described. The interventions
are clearly described. The
post‑intervention clinical
condition is not clear.
Adverse events are not
mentioned
The patient’s demographic
characteristics are not clearly
described.
Adverse events are not
mentioned

No selection criteria applied
prior to the invitation to
join this cohort study.
Participation rate was very
low. There was potential
selection bias

It was a partially
double‑blind study. The
groups were not similar at
the start of the trial. Aside
from the experimental
intervention, the groups were
not treated equally. Only an
exploratory analysis was
done
This article has been
retracted.
Retraction in: PLoS One.
2020 April 23; 15 (4):
e0232415.
(Contd...)
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Table 1: (Continued)
S. No.

Article

Study design/sample
size/instrument used

moderate to severe depression
in peri‑ and postmenopausal
women (HOMDEP‑MENOP
study): A randomised,
double‑dummy, double‑blind,
placebo‑controlled trial
(retracted in: PLoS One. 2020
Apr 23;15 (4):e0232415).
PLoS One. 2015;10
(3):e0118440. Published 2015
Mar 13. doi: 10.1371/journal.
pone. 0118440
Katz T, Fisher P, Katz A,
Davidson J, Feder G. The
feasibility of a randomised,
placebo‑controlled clinical
trial of homoeopathic
treatment of depression
in general practice.
Homoeopathy. 2005;94
(3):145‑52.
Oberai P,
Balachandran I, Janardhanan
Nair KR, Sharma A, Singh
VP, Singh V, Nayak C.
Homoeopathic management
in depressive episodes: A
prospective, unicentric,
non‑comparative, open‑label
observational study. Indian
J Res Homoeopathy
2013;7:116‑25.

A randomised,
double‑dummy,
double‑blind,
placebo‑controlled
trial

12.

13.

10.

11.

Quality

Strength

Limitation

used. A randomised, double‑dummy,
double‑blind, placebo‑controlled trial

The individualised
homoeopathic treatment
and the decision‑making
framework for treatment
adjustments were not
reported in sufficient detail.
The study design did not
include sufficient controls

CASP‑randomised
trial.
Sample size‑23.
Randomised,
double‑dummy,
double‑blind parallel
group clinical trial.
Setting:

Mild

The study addressed a clearly focused
research question. The assignment
of participants to interventions was
randomised. All participants who
entered the study were not accounted
for at its conclusion

Methodology was well
planned and rigorous.
However, cointerventions
are unknown.
However, recruitment was
scarce and loss to follow‑up/
withdrawals were more

Observational
studies, based on the
Newcastle–Ottawa
scale
Sample size‑83.
A prospective,
unicentric,
non‑comparative,
open‑label
observational study

Moderate

Confounding factors are not
explained or not accounted
in the design and/or analysis.
Follow‑up of this study was
short.

Novak MR. Integrative
sulpiride with a homoeopathic
therapy for treating depressive
syndrome – An observational
study. Psychiatria Danubina,
2011;23 (2):200‑201.

Observational
studies, based on the
Newcastle–Ottawa
scale.
Sample size‑82.
An observational
study.

Mild

The intensity of depression was
measured using validated scales
such as Hamilton Depression Rating
Scale (HDRS) and Beck Depression
Inventory (BDI). Other assessment
measures were the Clinical Global
Impression (CGI‑1) scale. A validated
measure of illness severity and
Clinical Global Improvement (CGI‑2)
owing to treatment. The data relating
to these questionnaires were collected
at baseline and at monthly intervals
for 12 months by the investigators
and consultant psychiatrist. The ITT
principle was applied for conducting
the analysis
Improvements were assessed with
HDRS scale.

del Carmen Maciías‑Cortées
Macías‑Cortés E, Llanes‑
GonzaálezGonzález L,
Aguilar‑Faisal L, Asbun
‑Bojalil J. Response to
individualised homoeopathic
treatment for depression in
climacteric women with a
history of domestic violence,
marital dissatisfaction or
sexual abuse: Results from
the HOMDEP‑MENOP study.
Homoeopathy. 2018 Aug; 107
(03):202‑8.

CASP‑randomised
trial.
Sample size‑133.
A randomised,
placebo‑controlled,
double‑blind,
double‑dummy,
three‑arm trial
follow‑up study

High

The severity of symptoms was
determined with two well‑known
standardised scales used. Risk factor
for depression was assessed

No information regarding
the effectiveness of specific
homoeopathic remedies and
potencies. The duration of
the study was too short. A
detail of participants was
not explicitly mentioned.
Not provided the details of
adverse effects. The details
of the study design were not
provided
The mental health
examination and any
standardised tool did
not specifically used for
evaluating DV, SA or MD.
First, sample size was
calculated for the primary
analysis, aiming to detect an
effect size

(Contd...)
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Table 1: (Continued)
S. No.

Article

Study design/sample
size/instrument used

Quality

Strength

Limitation

14.

Grimaldi‑Bensouda L,
Abenhaim L, Massol J,
Guillemot D, Avouac B,
Duru G, et al. Homoeopathic
medical practice for anxiety
and depression in primary
care: the EPI3 cohort study.
BMC Complement Altern
Med. 2016;16:125.
doi: 10.1186/
s12906‑016‑1104‑2.
PMID: 27145957;
PMCID: PMC4855343.
Mahwish N, Mehmood A,
Nauman AT. A study on the
curative action of Arsenicum
album in major depression.
European Journal of
Integrative Medicine. 2010;4
(2):226‑7.

Newcastle–Ottawa
Quality Assessment
Scale.
Sample size‑1562.
Cohort study.

Moderate

Variety of information collected at
baseline, covering sociodemographic
and clinical characteristics.
No instructions were given to
participating physicians or patients
to prevent interference. Three groups
were free to prescribe conventional
and/or homoeopathic drugs. Hospital
Anxiety and Depression Scale
(HADS) questionnaire had used.

Diagnoses of disease
symptoms were based on
own clinical judgement, of
general practitioners with no
attempt at standardisation
or external validation or
participation rate

JBI‑cross‑sectional
studies. It is a
cross‑sectional
qualitative and
quantitative research
work.
Sample size‑200
patients.
Observational
studies, based on the
Newcastle–Ottawa
scale observational
study.
Sample size‑1572.

Low

The approach of a single remedy

Particular medicine and
particular potency were
used for all the participants
without any clear evidence.
Assessment of symptom
reductions was not
mentioned

High

High representativeness of the
patients. Quality assessment is done.

The design does not allow for
addressing the directionality
of the associations
described between patients’
characteristics and their
physician’s choice of
medical practice. The
participants recruited in
primary care might have
excluded people with severe
psychiatric disorders. This
potential bias was likely to
underestimate the prevalence
of psychotropic drug use
The most common difficulty
was in cases where a patient
presented with two discrete
medical conditions that
were treated separately with
two different homoeopathic
medicines.
The study duration was
brief. The rating scale for
depression was not used
Assessment is not
mentioned. Characteristics
of the patients are not
mentioned. Recruitment
details are not mentioned.
The study was not done
prospectively. Statistical
tests were not used.
Follow‑ups were not long
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by homoeopaths for patients with self-reported depression was
associated with a small treatment effect over a time period of
6–12 months, whereas a moderate effect was found in patients

who received treatment. However, wide confidence intervals
preclude any firm conclusions from being drawn. Fourteen
adverse effects were also noticed.[29]
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Another trial conducted by Adler et al. in 2011 aimed to
investigate the non-inferiority and tolerability of individualised
homoeopathic medicines (Quinquagintamillesmial
[Q-potencies]) in acute depression, using fluoxetine as an
active control. This study indicated the non-inferiority of
individualised homoeopathic Q-potencies as compared to
fluoxetine in the acute treatment of outpatients with moderateto-severe depression.[30]
Further, among the five placebo-controlled randomized
trials identified for this review is a feasibility trial that was
conducted by T Katz et al. to assess the feasibility of a general
practice-based clinical trial comparing the effectiveness of
individualised homoeopathic treatment versus fluoxetine
(Prozac) versus placebo in the treatment of MDEs of moderate
severity. It displayed that a trial of this design in general
practice is not feasible because of recruitment difficulties,
many of them linked to patient preference.[31]
A randomised, partially double-blind, placebo-controlled,
four-armed study, by Adler et al., was terminated because
of recruitment problems.[32] A randomised, double-blind and
placebo-controlled was done by Bagherian et al.; findings
exhibit that homoeopathic therapy can be used as an effective
method to treat depression disorders.[33] A randomised,
double-dummy, double-blind, placebo-controlled trial,
which was conducted by Macías-Cortés et al. to assess the
efficacy and safety of individualised homoeopathic treatment
versus placebo and fluoxetine versus placebo in peri- and
postmenopausal women with moderate-to-severe depression
shown that the homoeopathic group was more effective than
placebo.[34] In 2018, a randomised, placebo-controlled, doubleblind, double-dummy, three-arm trial on HOMDEP-MENOP
study was conducted by Macías-Cortés who had shown a
statistically significant association with response to depression
treatment.[35]
Seven observational studies identified were highly
heterogeneous and could be presented in an aggregated
form only to a limited extent. The objectives and outcomes
used were combined and standard reporting guidelines for
observational studies were followed by only a few of these.
Both classical homoeopathy and adjuvant treatment with the
standard treatment showed clinical improvement, as well as
on the standard scales Hamilton Depression Rating Scale
(HDRS), Beck Depression Inventory (BDI) and Clinical Global
Impression.[18,36-41]
RT Mathie et al conducted a pilot data collection study, in which
14 homoeopathic physicians collected clinical and outcomes
data over a 6-month period in their practice setting. A total of
1783 individual patient conditions were treated overall. The
outcome from two or more homoeopathic appointments per
patient condition was obtained in 961 cases (75.9% positive,
4.6% negative, 14.7% no change; 4.8% outcome not recorded).
Strongly positive outcomes were achieved most notably in
anxiety, and depression.[42]
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A semi-structured qualitative interview study was done within
a randomized controlled trial to learn about depressed patients’
experiences with the treatment provided by homoeopaths.
Patients were interviewed to recall from their experiences
with the intervention and to compare their experiences
with antidepressants and other depression interventions.
This qualitative study provided the first understanding of
depressed patients’ experiences with the treatment provided
by homoeopaths as an adjunct to usual care. Their experiences
with the consultation were described through themes such as
caring support and trust, and shared several similarities with
“talking therapy” interventions. The results of this research
may be of relevance to patients and providers considering
homoeopathic treatment for depressed patients.[43]
The case series by R. Itamura stated that 13 patients had a
signiﬁcant process of cure from chronic depression through
homoeopathy for 2 years. All patients were diagnosed as
having MDDs with the DSM-IV and treated already several
antidepressants. Cases were considered recovered when
antidepressants had been stopped for 6 months and 3 months
had passed since the stopping of homoeopathic medicines.[44]
Another one by Adler et al. in 2008, with the objective to report
preliminary results of homoeopathic treatment of depression
in Jundiai’s public health system, Sao Paulo. The medical
records of patients who received individualised homoeopathy
treatment for depression in between March and December
2006 were reviewed. The outcome and symptoms severities
were measured with Montgomery and Åsberg Depression
Scale (MADRS). Fifteen patients were treated and response
(more than 50% decrease of MADRS scores) was observed in
14 patients (93%), after an average of 7 weeks of treatment;
one patient had clinical worsening and the remaining patients’
results were significant.[45]
A case report of postpartum psychosis showed significant
improvement. The Edinburgh postnatal depression scale,
positive and negative syndrome scale and global assessment
of functionality scale were used to measure clinical outcomes
in symptom severity and treatment efficacy in subjects
with psychoses. [46] Another case presented with severe
depression with psychosis symptoms. Hamilton Depression
Rating Scale and Brief Psychiatric Rating Scale were used
to measure the clinical outcome and symptom severity.
The patient had significant improvement in social life and
functioning with standalone homoeopathic treatment. Even
the acute exacerbation was also managed with individualised
homoeopathic medicine during the depressive episode.[47]

Discussion
This review provides a comprehensive overview of the
evidence of Homoeopathy in treatment of Depression.
All attempts were made to recover both published peerreviewed studies and reports available online. The authors
assure that the entire relevant literature available in English
language, within the specified time, was identified for the
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review, though it is expected that some studies might have
got missed inadvertently. Also, the extent of missing data
from unpublished studies is not known. Although the review
found substantial clinical trial literature, the presence of
basic methodological weaknesses and of comorbidities in the
recruited participants led to the exclusion of many studies.
The results for non-English studies were not considered,
which might have led to selection bias. The studies published
in non-peer-reviewed journals were also excluded. Such
studies provide only relatively weak evidence of effectiveness.
Hence,only the studies fulfilling the inclusion criteria were
assessed. It is also pertinent to mention that three RCTs
included in this study were also a part of the two systematic
reviews included for the present synthesis.[27,28,30-32]
Based on the assessment criteria, the studies were subdivided
into mild, moderate and high categories. It may be noted that
this quality assessment was specific to each paper regardless
of the paper type. Hence, one may observe that an RCT has
scored a mild or moderate grade, while a case report has scored
a high grade. Quality assessment of three studies could not be
done due to their heterogeneity.
The trials selected for the synthesis were entirely heterogeneous,
as reported earlier, in terms of the type of homoeopathy used,
outcome measures, types of depression, methodological
qualities, risk of bias and quality of individualisation. There
were trials assessing the efficacy of homoeopathic medicines;
those assessing the effectiveness of treatment by homoeopaths
and those describing the outcomes of patients treated by
homoeopaths.
The outcome measures were used to measure the reliability
of responses and assist in objective assessment, diagnosis and
monitoring of the patient outcome. These scales can easily
be incorporated into clinical practice, which would help in
following the progression of symptoms and the effectiveness
of treatment.
Individualised homoeopathy was used in 13 studies, and
single medicine Arsenicum album in 1 study, and complex
homoeopathic remedies in another study. Even though three
different prescribing strategies were used in the included studies
i, positive results were obtained from all three. It is difficult
to construct an analysis from the same. The uncontrolled
studies were of poor quality, most of them not mentioning the
methods, assessment tools, type of intervention and severity
of depression of the population under study.
The RCTs, even though with differing risks of bias and model
validity, provide evidence that homoeopathy has a positive role
in the treatment of homoeopathy.
However, overall, the review shows that there is a paucity of
high quality literature on Homoeopathy in depression . Most
of the studies fall under the moderate and mild qualities of
evidence. The most common reasons for the studies categorized
as mild were inadequate sample size, short duration, poor
description of the methods used, deviation from standard

criteria for grouping the samples, unequal ratio of sample size,
and inadequate details of the questionnaires and scales used.
Some studies have not used standardised and valid scales.
Some studies had used substandard methods of treatment[36]
while the results of some of the studies appeared hard to
accept.[39] The standard guidelines may improve the content
of the research, improve the utility of the research report and
reduce the bias. From the limitations mentioned, researchers
can avoid potential mistakes. The understanding of the scope,
limitations and prognosis of individualised as well as add-on
homoeopathic treatment in depressive disorder, can influence
the treatment of homoeopathic practitioners.
Depression, being a common and recurrent disorder, needs
long-term follow-ups. None of the studies had a long-term
assessment, reasonable enough to state that homoeopathy has
a curative and preventive effect on depression. The diagnostic
criteria were only clearly mentioned in eight studies (either
ICD or DSM).
Only two randomised active control trials and five placebocontrolled trials made it to the final inclusion. The authors
found that most of them were not following the Consolidated
Standards of Reporting Trials (CONSORT).[48] Only two out
of the seven studies had a sample size above 100.[34,35] Less
number of participants was one of the main drawbacks that
could be identified. One study, however, which was terminated
due to poor recruitment had a robust research design.[32] Six out
of seven RCTs had proper blinding strategies. Randomisation
was done adequately in six studies. Allocation concealment
was mentioned properly in two studies. Among all RCTs, the
maximum duration of the study was 9 months, which was
seen in two studies.

Implications for clinical practice

Even though the individualised homoeopathic approach often
yields good clinical results, it has not yet been able to render
positive outcomes in the scientific literature because of a
myriad of methodological weaknesses. Thus, the evidence
underpinning the usefulness of homoeopathy in depression
remains unconvincing, even though these studies, when
considered separately, seem to make a reliable statement Two
following studies not considered in this review have similar
outcomes. An observational survey conducted in France
between 2007 and 2008, on the patients with depressive
disorders has shown a positive effect of homoeopathy in its
effectiveness and lower psychotropic drug use.[40]
Statistical analysis of 156 cases of depression treated with
classical homoeopathy selected from Vithoulkas Compass
online homoeopathic software and women reported a better
response to homoeopathy.[37]

Implications for future research

As narrated above, the currently available literature in
homoeopathy has a lucid theoretical framework that could be
used as the foundation for experimental studies to examine
their effect. Most of the studies have very poor adherence to
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reporting guidelines. It is recommended that authors, reviewers
and editors comply with available reporting guidelines suitable
for homoeopathic trials (HOM CASE, etc.). Furthermore, the
standard guidelines and tools, as applicable, should be utilised
during protocol development.
Collaborative multicentric trials to evaluate the safety,
feasibility and efficacy of the homoeopathic intervention in
treating various stages and severity of depression is the need of
the hour. Experimental studies, with robust methodologies and
validated intervention protocols, are lacking and are warranted
in future. High-quality, non-inferiority or equivalence efficacy
and safety trials evaluating Homoeopathy as a treatment option
as a standalone or adjuvant, may be designed for drawing
conclusions.

9.
10.
11.
12.
13.
14.
15.
16.

Conclusion
This review is an attempt in synthesising the existing literature
on the effectiveness of homoeopathy in the treatment of
depression. However, to obtain more reliable results, further
research may be better designed, with long-term follow-ups.
It is also suggested that future efforts also emphasise the
adverse effects, as much as they emphasise the efficacy of
homoeopathic treatment.
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Portée de l'homéopathie dans le traitement de la dépression: Une synthèse narrative
Contexte: La dépression est un trouble d'une importance majeure pour la santé publique, en termes de prévalence et de souffrance,
de dysfonctionnement, de morbidité et de charge économique. La dépression est l'une des affections les plus courantes pour
lesquelles les gens recherchent un traitement homéopathique.. Objectif: Cette étude vise à comprendre la portée de l'homéopathie
dans la dépression en se basant sur les résultats des études précédentes. Méthodes: Une étude a été réalisée afin d'évoquer la
portée des médicaments homéopathiques dans le traitement de la dépression. Des recherches ont été effectuées dans des bases
de données générales et spécialisées. Les données ont été collectées dans des journaux évalués par des pairs et publiés entre
janvier 2001 et janvier 2021. Des efforts ont été faits pour identifier les articles publiés sur "la dépression et l'homéopathie",
"l'homéopathie pour la dépression", "le trouble dépressif et l'homéopathie", et "la dysthymie en homéopathie".Résultat: Vingt
et une études pertinentes ont été trouvées et incluses dans l'examen. Il s'agissait de revues systématiques, d'essais contrôlés
randomisés, d'études d'observation, de séries de cas et de rapports de cas. Même si les études prises en compte dans l'examen
indiquent l'efficacité de l'homéopathie, il est difficile d'évaluer l'effet global de l'homéopathie de manière systématique,
principalement en raison des conceptions d'étude compromises.. Conclusion: Cette revue a permis de synthétiser la littérature
existante sur la portée de l'homéopathie dans le traitement de la dépression. Cependant, afin d'obtenir des résultats plus fiables,
des recherches mieux conçues, avec des suivis à long terme, peuvent être planifiées..
Der Anwendungsbereich der Homöopathie bei der Behandlung von Depressionen: Eine erzählerische Synthese
Hintergrund: Depressionen sind eine Erkrankung, die aufgrund ihrer Prävalenz, ihres Leidens, ihrer Dysfunktion, ihrer
Morbidität und ihrer wirtschaftlichen Belastung von großer Bedeutung für die öffentliche Gesundheit ist. Depressionen sind eine
der häufigsten Erkrankungen, bei denen Menschen eine homöopathische Behandlung suchen. Zielsetzung: Ziel dieser Studie ist
es, den Anwendungsbereich der Homöopathie bei Depressionen auf der Grundlage der Ergebnisse früherer Studien zu verstehen..
Methoden: Es wurde eine Studie durchgeführt, um den Anwendungsbereich homöopathischer Arzneimittel bei der Behandlung
von Depressionen aufzuzeigen. Es wurde sowohl in allgemeinen als auch in spezialisierten Datenbanken recherchiert. Die Daten
wurden in begutachteten Fachzeitschriften gesammelt, die zwischen Januar 2001 und Januar 2021 veröffentlicht wurden. Es wurde
versucht, veröffentlichte Artikel zu den Themen "Depression und Homöopathie", "Homöopathie bei Depressionen", "Depressive
Störungen und Homöopathie" und "Dysthymie in der Homöopathie" zu finden.Ergebnis: Es wurden einundzwanzig relevante
Studien gefunden und in die Überprüfung einbezogen. Dazu gehörten systematische Übersichten, randomisierte Kontrollstudien,
Beobachtungsstudien, Fallserien und Fallberichte. Auch wenn die in der Übersichtsarbeit berücksichtigten Studien auf die
Wirksamkeit der Homöopathie hinweisen, ist es schwierig, die Gesamtwirkung der Homöopathie systematisch zu bewerten, vor
allem wegen der unzureichenden Studiendesigns. Schlussfolgerung: Diese Übersichtsarbeit hat dazu beigetragen, die vorhandene
Literatur über den Anwendungsbereich der Homöopathie bei der Behandlung von Depressionen zusammenzufassen. Um jedoch
verlässlichere Ergebnisse zu erhalten, sollten besser konzipierte Studien mit langfristiger Nachbeobachtung geplant werden..
अवसाद की चिकित्सा में होम्योपैथी का दायरा: एक वृतांत संकलन
पृष्ठभूमि: अवसाद व्यापकता एवं पीड़ा, शिथिलता, रुग्णता और आर्थिक बोझ के संदर्भ में प्रमुख सार्वजनिक स्वास्थ्य महत्व का विकार है ।
अवसाद सबसे आम स्थितियों में से एक है जिसके लिए लोग होम्योपैथिक उपचार चाहते हैं । उद्दे श्य: इस अध्ययन का उद्देश्य पिछले अध्ययनों
के परिणामों के आधार पर अवसाद में होम्योपैथी के दायरे को समझना है । विधि: अवसाद के उपचार में होम्योपैथिक दवाओं के दायरे को
स्पष्ट करने के लिए एक अध्ययन किया गया था। खोज सामान्य और विशेष दोनों डे टाबेस में की गई । जनवरी 2001 से जनवरी 2021 के बीच
प्रकाशित शिष्ट समीक्षा पत्रिकाओं से जानकारी एकत्र की गयी। "अवसाद और होम्योपैथी", "अवसाद के लिए होम्योपैथी", "अवसादग्रस्तता
विकार और होम्योपैथी" और "मानसिक कष्ट में होम्योपैथी " पर प्रकाशित लेखों की पहचान करने का प्रयास किया गया । . परिणाम: इक्कीस
प्रासंगिक अध्ययन पाए गए और समीक्षा में शामिल किए गए। इनमें व्यवस्थित समीक्षा, यादृच्छिक नियंत्रण परीक्षण, अवलोकन संबंधी अध्ययन,
विषय श्रृंखला और विषय व्याख्या शामिल हैं । भले ही समीक्षा में किए गए अध्ययनों से होम्योपैथी की प्रभावशीलता का संकेत मिलता है , परं तु
अधिकां शतः दोषयुक्त अध्ययन संरचना के कारण होम्योपैथी के समग्र प्रभाव का व्यवस्थित रूप से मूल्यां कन करना मुश्किल है । निष्कर्ष: इस
समीक्षा ने अवसाद के उपचार में होम्योपैथी के दायरे पर मौजूदा साहित्य को संश्लेषित करने में मदद की है । परं तु, अधिक विश्वसनीय परिणाम
प्राप्त करने के लिए , लंबी अवधि के परामर्श के साथ-साथ बेहतर अध्ययन संरचना किए गए अनुसंधानों की योजना बनाई जा सकती है ।
Alcance de la Homeopatía en el Tratamiento de la Depresión: Una Síntesis Narrativa
Fundamento: La depresión es un trastorno de gran importancia para la salud pública, en términos de prevalencia y sufrimiento,
disfunción, morbilidad y carga económica. La depresión es una de las condiciones más comunes para las cuales las personas
buscan tratamiento homeopático. Objetivo: El objetivo de este estudio es comprender el alcance de la homeopatía en la depresión
a partir de los resultados de estudios previos. Métodos: Se realizó un estudio para descubrir el alcance de los medicamentos
homeopáticos en el tratamiento de la depresión. Las búsquedas se realizaron tanto en bases de datos generales como especializadas.
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Los datos se recopilaron de revistas revisadas por expertos publicadas entre enero de 2001 y enero de 2021. Se procuró identificar
artículos publicados sobre “depresión y homeopatía”, “homeopatía para la depresión”, “trastorno depresivo y homeopatía” y
“distimia en la homeopatía”. Resultado: Se encontraron 21 estudios relevantes que se incluyeron en la revisión. Estas incluyeron
revisiones sistemáticas, ensayos de control aleatorios, estudios observacionales, series de casos e informes de casos. Aunque los
estudios considerados en la revisión indican la eficacia de la homeopatía, es difícil evaluar sistemáticamente el efecto general
de la homeopatía, sobre todo debido a diseños de estudio comprometidos. Conclusión: Esta revisión ha ayudado a sintetizar
la literatura existente sobre el alcance de la homeopatía en el tratamiento de la depresión. Sin embargo, para obtener resultados
más confiables, se pueden planificar investigaciones mejor diseñadas, con seguimiento a largo plazo.
顺势疗法治疗抑郁症的范围。叙述性综述
背景介绍: 抑郁症是一种具有重大公共卫生意义的疾病，就其发病率和痛苦、功能障碍、发病率和经济负担而言。.
抑郁症是人们寻求顺势治疗的最常见情况之一。. 目标: 本研究旨在根据以往的研究结果，了解顺势疗法在抑郁症中
的应用范围。. 方法: 进行了一项研究，以显示同种疗法药物在治疗抑郁症方面的作用。. 在一般和专门的数据库
中都进行了搜索. 数据收集自2001年1月至2021年1月期间出版的同行评议的期刊. 我们努力寻找已发表的关于 "抑
郁症和顺势疗法"、"顺势疗法治疗抑郁症"、"抑郁症和顺势疗法 "以及 "顺势疗法中的抑郁症 "的文章。. 结果。
发现了21项相关研究，并将其纳入综述。. 这些研究包括系统回顾、随机对照试验、观察性研究、系列病例和个案
报告。. 即使审查中所考虑的研究表明了顺势疗法的有效性，但很难系统地评估顺势疗法的整体效果，主要是因为
研究设计受到了影响。. 总结: 本综述有助于综合现有文献，了解顺势疗法在治疗抑郁症方面的范围。. 然而，为
了获得更可靠的结果，可以计划进行设计更好的研究，并进行长期的跟踪调查。.
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